CO2019000120A2 - Preparación de derivados del factor xa - Google Patents

Preparación de derivados del factor xa

Info

Publication number
CO2019000120A2
CO2019000120A2 CONC2019/0000120A CO2019000120A CO2019000120A2 CO 2019000120 A2 CO2019000120 A2 CO 2019000120A2 CO 2019000120 A CO2019000120 A CO 2019000120A CO 2019000120 A2 CO2019000120 A2 CO 2019000120A2
Authority
CO
Colombia
Prior art keywords
protein
preparation
chromatograph
factor derivatives
sti
Prior art date
Application number
CONC2019/0000120A
Other languages
English (en)
Inventor
Mark Karbarz
Pamela B Conley
Genmin Lu
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019000120(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of CO2019000120A2 publication Critical patent/CO2019000120A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)

Abstract

La presente descripción proporciona métodos para fabricar una proteína derivada de fXa a gran escala, lo que produce un alto rendimiento de producto proteico altamente puro. El método puede incluir agregar un detergente a una muestra que contiene una construcción de polinucleótidos que codifica la proteína y purifica la proteína a través de un cromatógrafo por afinidad basado en el inhibidor la tripsina de soja (STI), un cromatógrafo de modo mixto y de intercambio de iones y una interacción hidrofóbica.
CONC2019/0000120A 2016-06-17 2019-01-09 Preparación de derivados del factor xa CO2019000120A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Publications (1)

Publication Number Publication Date
CO2019000120A2 true CO2019000120A2 (es) 2019-03-29

Family

ID=60663351

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0000120A CO2019000120A2 (es) 2016-06-17 2019-01-09 Preparación de derivados del factor xa

Country Status (23)

Country Link
US (4) US10604748B2 (es)
EP (2) EP3926044A1 (es)
JP (3) JP6959268B2 (es)
KR (1) KR102373215B1 (es)
CN (2) CN110167575B (es)
AU (2) AU2017283720B2 (es)
BR (1) BR112018075964A2 (es)
CA (1) CA3027457A1 (es)
CL (2) CL2018003654A1 (es)
CO (1) CO2019000120A2 (es)
DK (1) DK3472314T3 (es)
EA (1) EA037815B1 (es)
ES (1) ES2875538T3 (es)
HU (1) HUE054597T2 (es)
IL (1) IL263591B2 (es)
MX (1) MX2018015873A (es)
PE (1) PE20190661A1 (es)
PH (1) PH12018502614A1 (es)
PL (1) PL3472314T3 (es)
PT (1) PT3472314T (es)
SG (1) SG11201810915QA (es)
SI (1) SI3472314T1 (es)
WO (1) WO2017219034A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268783B2 (en) * 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
US20150352194A1 (en) * 2013-01-24 2015-12-10 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
MX2018015873A (es) * 2016-06-17 2019-08-12 Portola Pharm Inc Preparacion de derivados del factor xa.
WO2019246094A1 (en) * 2018-06-19 2019-12-26 Portola Pharmaceuticals, Inc. Antidotes to factor xa inhibitors
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) * 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
ATE549317T1 (de) 2005-11-08 2012-03-15 Millennium Pharm Inc Pharmazeutische salze und polymorphe aus n-(5- chloro-2-pyridinyl)-2-ää4- ä(dimethylamino)iminomethylübenzoylüaminoü-5- methoxy-benzamid, einem faktor-xa-hemmer
CA2697583C (en) 2007-09-28 2016-04-12 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
US8268783B2 (en) 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
CA2743496C (en) 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
CA2767858C (en) * 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
PT2861614T (pt) * 2012-06-14 2017-01-26 Portola Pharm Inc Método para a purificação de derivados do fator xa recombinantes
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US20150352194A1 (en) 2013-01-24 2015-12-10 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
EP3049434A1 (en) * 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP3182993B1 (en) * 2014-08-20 2020-07-01 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
MX2018015873A (es) * 2016-06-17 2019-08-12 Portola Pharm Inc Preparacion de derivados del factor xa.

Also Published As

Publication number Publication date
JP7273918B2 (ja) 2023-05-15
AU2017283720B2 (en) 2022-11-17
US20170369862A1 (en) 2017-12-28
EP3926044A1 (en) 2021-12-22
US10604748B2 (en) 2020-03-31
EA037815B1 (ru) 2021-05-25
EP3472314A2 (en) 2019-04-24
KR102373215B1 (ko) 2022-03-10
CA3027457A1 (en) 2017-12-21
US10954504B2 (en) 2021-03-23
AU2017283720A1 (en) 2019-01-03
DK3472314T3 (da) 2021-07-26
CN110167575A (zh) 2019-08-23
US11845966B2 (en) 2023-12-19
PT3472314T (pt) 2021-06-18
SG11201810915QA (en) 2019-01-30
IL263591B2 (en) 2023-03-01
ES2875538T3 (es) 2021-11-10
PL3472314T3 (pl) 2021-11-22
EA201990052A1 (ru) 2019-05-31
US20210348149A1 (en) 2021-11-11
EP3472314B1 (en) 2021-05-05
CN116425860A (zh) 2023-07-14
MX2018015873A (es) 2019-08-12
PH12018502614A1 (en) 2019-09-30
JP6959268B2 (ja) 2021-11-02
JP2023086970A (ja) 2023-06-22
WO2017219034A2 (en) 2017-12-21
JP2019528242A (ja) 2019-10-10
SI3472314T1 (sl) 2021-11-30
US20240076642A1 (en) 2024-03-07
IL263591B (en) 2022-11-01
JP2022000477A (ja) 2022-01-04
AU2023200825A1 (en) 2023-03-16
IL263591A (en) 2019-02-03
PE20190661A1 (es) 2019-05-08
HUE054597T2 (hu) 2021-09-28
CL2018003654A1 (es) 2019-01-25
CN110167575B (zh) 2024-03-15
CL2020001733A1 (es) 2020-09-25
US20200208131A1 (en) 2020-07-02
EP3472314A4 (en) 2020-01-22
BR112018075964A2 (pt) 2019-04-02
WO2017219034A3 (en) 2019-03-14
KR20190019134A (ko) 2019-02-26

Similar Documents

Publication Publication Date Title
CO2019000120A2 (es) Preparación de derivados del factor xa
MX2021005353A (es) Composiciones, metodos y sistemas para el analisis de la corona proteica y usos de los mismos.
AU2017228470A8 (en) Combination therapy with anti-CD73 antibodies
EA201792529A1 (ru) Ингибиторы тирозинкиназы
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
BRPI0509110A8 (pt) Método e dispositivo para processar um sinal estéreo, aparelhos codificador e decodificador, e, sistema de áudio
RU2009109904A (ru) Способ локализации источников электромагнитного излучения декаметрового диапазона
ECSP12011871A (es) Antagonistas de il-17a
CL2017001561A1 (es) Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas
BR112018000702A2 (pt) ?processo para preparação de um composto e, uso de um material zeolítico contendo boro?
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
BR112019005963A2 (pt) equipamento de cura aperfeiçoado e seus métodos de uso
MX2022000893A (es) Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas.
EA201792012A1 (ru) Использование щелочных промывочных растворов во время хроматографии для удаления примесей
BR112018074238A2 (pt) combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b
WO2016154623A3 (en) Anti-cd133 monoclonal antibodies and related compositions and methods
EP4235179A3 (en) Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker
CL2018002466A1 (es) Proceso mejorado para la elaboración de un tablero aglomerado
FR3050738B1 (fr) Microorganismes temoins de decontamination
BR112018015626A2 (pt) sistema fúngico de produção de alto nível de proteínas
EP3536805A3 (en) Analytical methods and arrays for use in the same
AR110871A1 (es) Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas
WO2018013551A8 (en) Tools for next generation komagataella (pichia) engineering